Related Experiment Video
Updated: Jul 11, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
The International Harmonization Project for response criteria in lymphoma clinical trials
1Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA. bdc4@georgetown.edu
Abstract:
Clinical trials are critical to the development of newer and more effective treatments. Standardized response criteria are essential to assess and compare the activity of various therapies within and among studies and to facilitate the evaluation of new treatments by regulatory agencies. The International Harmonization Project developed revised guidelines with the goal of improved comparability among studies, leading to accelerated new agent development resulting in the rapid availability of improved therapies for patients who have lymphoma. Modifications of these recommendations are expected as new information and improved technologies become available.
Insights
Standardized criteria for clinical trials help evaluate new lymphoma treatments. Revised guidelines aim for better study comparability, speeding up the development of effective therapies for patients.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Clinical trials are vital for developing novel and effective medical treatments.
- Standardized response criteria are crucial for assessing therapy efficacy across studies and for regulatory review.
Purpose of the Study:
- To present revised guidelines from the International Harmonization Project for assessing treatment response in lymphoma.
- To enhance comparability among clinical studies and accelerate the development of new lymphoma therapies.
Main Methods:
- Development of revised guidelines for standardized response criteria in lymphoma clinical trials.
- International collaboration and consensus-building among experts.
Main Results:
- Establishment of updated guidelines to improve the assessment and comparison of lymphoma treatment activity.
- Facilitation of more direct comparisons between different therapeutic agents and study outcomes.
Conclusions:
- Revised guidelines are expected to improve the comparability of clinical trial data for lymphoma.
- These advancements aim to accelerate the availability of improved therapies for patients with lymphoma.
- Future modifications are anticipated with new data and technological advancements.